Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06564038 · ClinicalTrials.gov registry record · Phase 1

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

A Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
276
Enrollment target
20
Study locations

NCT06564038: Recruiting Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma, sponsored by AstraZeneca.

NCT06564038 is a Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 276 participants, above the 101-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06564038, a Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
276 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

Primary Outcome

Safety and tolerability of surovatamig as monotherapy and in combination with other anticancer agents across mature B-cell malignancies.

Conditions Studied

Mantle Cell Lymphoma Small Lymphocytic Lymphoma Large B-cell Lymphoma B-Cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukaemia

Interventions

  • DRUG Cyclophosphamide
  • DRUG Rituximab
  • DRUG Vincristine
  • DRUG AZD0486
  • DRUG Prednisone (or equivalent)

Study Locations (20)

Other

  • Research Site - Heidelberg
  • Research Site - Melbourne
  • Research Site - Nedlands
  • Research Site - Beijing
  • Research Site - Guangzhou
  • Research Site - Jinan
  • Research Site - Tianjin

New Jersey

  • Research Site - Hackensack
  • Research Site - New Brunswick

New York

  • Research Site - New York
  • Research Site - New York

North Carolina

  • Research Site - Charlotte
  • Research Site - Charlotte

Pennsylvania

  • Research Site - Philadelphia
  • Research Site - Pittsburgh

Massachusetts

  • Research Site - Boston

Ohio

  • Research Site - Columbus

Oregon

  • Research Site - Portland

Trial Details

FieldValue
Enrollment Target 276 participants
Start Date 2025-01-30
Est. Completion 2028-02-28
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT06564038 shows while recruiting

NCT06564038 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (173% higher).

The record links to 5 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT06564038 names 20 study sites across 10 states, led by Other, New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT06564038 about?

NCT06564038 is a clinical study titled "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies". The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

What is the current status of trial NCT06564038?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2025-01-30. Estimated completion is 2028-02-28.

What conditions does trial NCT06564038 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Large B-cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia.

What interventions are being tested in trial NCT06564038?

The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Vincristine (DRUG), AZD0486 (DRUG), Prednisone (or equivalent) (DRUG).

Who is sponsoring clinical trial NCT06564038?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06564038 being conducted?

This trial has 20 study locations across Massachusetts, New Jersey, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06564038's enrollment target sits among peer trials

276 12th of 102 higher than 91 of 102 other Mantle Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01371630 · 276 participants · Phase 1

    Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

  • NCT04192344 · 276 participants · Phase 1

    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

  • NCT05294991 · 276 participants · NA

    Wellness App for Sleep Disturbance in Hematological Cancer Patients

  • NCT05610852 · 276 participants · NA

    Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06564038

Source: ClinicalTrials.gov NCT06564038, the US trial registry maintained by the National Library of Medicine. NCT06564038 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.